Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-GRT7039 for Knee Osteoarthritis Pain
NCT05377489Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Sep 2022
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of RTX-GRT7039 in osteoarthritis (OA), sponsored by Grünenthal GmbH. Primary endpoints: Treatment-Emergent Adverse Events at 78 weeks and Treatment-Emergent Adverse Events Leading to Study Discontinuation at 78 weeks. Started Sep 2022; status: completed.
02
Drugs
RTX-GRT7039
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05377489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05377489.